"Dermatomyositis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)
Descriptor ID |
D003882
|
MeSH Number(s) |
C05.651.594.819.500 C10.668.491.562.575.500 C17.300.250 C17.800.185
|
Concept/Terms |
Dermatomyositis- Dermatomyositis
- Dermatomyositides
- Juvenile Myositis
- Juvenile Myositides
- Myositides, Juvenile
- Myositis, Juvenile
- Dermatopolymyositis
- Dermatopolymyositides
- Polymyositis-Dermatomyositis
- Polymyositis Dermatomyositis
- Polymyositis-Dermatomyositides
- Juvenile Dermatomyositis
- Dermatomyositides, Juvenile
- Dermatomyositis, Juvenile
- Juvenile Dermatomyositides
Dermatomyositis, Adult Type- Dermatomyositis, Adult Type
- Adult Type Dermatomyositides
- Adult Type Dermatomyositis
- Dermatomyositides, Adult Type
Dermatomyositis, Childhood Type- Dermatomyositis, Childhood Type
- Childhood Type Dermatomyositides
- Childhood Type Dermatomyositis
- Dermatomyositides, Childhood Type
|
Below are MeSH descriptors whose meaning is more general than "Dermatomyositis".
Below are MeSH descriptors whose meaning is more specific than "Dermatomyositis".
This graph shows the total number of publications written about "Dermatomyositis" by people in this website by year, and whether "Dermatomyositis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 0 | 2 |
1995 | 2 | 0 | 2 |
1996 | 3 | 0 | 3 |
1997 | 1 | 1 | 2 |
1998 | 0 | 1 | 1 |
1999 | 1 | 0 | 1 |
2000 | 0 | 1 | 1 |
2002 | 1 | 1 | 2 |
2003 | 1 | 0 | 1 |
2005 | 1 | 1 | 2 |
2006 | 2 | 0 | 2 |
2007 | 1 | 0 | 1 |
2008 | 2 | 0 | 2 |
2009 | 2 | 0 | 2 |
2013 | 1 | 1 | 2 |
2014 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
2017 | 1 | 0 | 1 |
2018 | 4 | 0 | 4 |
2019 | 2 | 0 | 2 |
2020 | 1 | 0 | 1 |
2021 | 2 | 0 | 2 |
2022 | 3 | 0 | 3 |
2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dermatomyositis" by people in Profiles.
-
Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features. Rheumatology (Oxford). 2023 02 23; 62(SI2):SI226-SI234.
-
Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies. Ann Rheum Dis. 2023 Feb; 82(2):235-245.
-
Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis. Rheumatology (Oxford). 2022 07 06; 61(7):2969-2977.
-
Environmental factors associated with juvenile idiopathic inflammatory myopathy clinical and serologic phenotypes. Pediatr Rheumatol Online J. 2022 Apr 12; 20(1):28.
-
Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis. Rheumatology (Oxford). 2021 05 14; 60(5):2134-2145.
-
Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. Rheumatology (Oxford). 2021 04 06; 60(4):1839-1849.
-
Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Res Ther. 2020 04 06; 22(1):69.
-
Long-term outcomes in Juvenile Myositis patients. Semin Arthritis Rheum. 2020 02; 50(1):149-155.
-
Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2019 07; 78(7):988-995.
-
Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Rheumatology (Oxford). 2018 11 01; 57(11):1956-1963.